Answers are grounded in this paper and cite their sources.
Introduction This study aims to systematically elucidate the specific targets and molecular mechanisms by which modified Chaihu Shugan San (mCSS) inhibits hepatocellular carcinoma (HCC) progression to link potential targets with cell cycle and immune microenvironment. Methods mCSS targets were first predicted via TCM databases, followed by functional enrichment analysis and drug-target-pathway network construction. TCGA HCC transcriptomic data underwent differential expression analysis and clinical screening to obtain prognosis-related differentially expressed genes. Core herbal formula-modulated targets were identified by intersecting predicted drug targets with these prognostic genes. Public HCC single-cell RNA-seq data was analyzed to characterize single-cell expression patterns of core targets for mechanism exploration. Finally, the pharmacological effects were validated via serum pharmacology assays in HCC cell lines. Results Network pharmacology analysis identified 319 potential targets of mCSS for HCC treatment. Transcriptomic analysis of TCGA data revealed 353 differentially expressed prognosis‑related genes. Intersection analysis uncovered 11 core targets: SPP1, AKR1C3, MMP9, PPIA, XDH, EPHX2, CDK4, GAPDH, HSP90AA1, LGALS1, and ADAM9. Single-cell data analysis demonstrated that CDK4 expression was markedly elevated in hepatoma cells (R=0.226,P < 0.001) and fibroblasts (R=0.117,P < 0.001), whereas LGALS1 expression was significantly increased in fibroblasts (R=0.426,P < 0.001) and T cells (R=0.348,P < 0.001). Cell-cell communication analysis indicated enhanced fibroblast-mediated communication and collagen-related signaling in HCC. In Hepa1–6 cells, mCSS-containing serum inhibited cell proliferation (P < 0.05) and migration and reduced CDK4 protein expression and Rb phosphorylation. Moreover, scTenifoldKnk-based virtual knockout of CDK4 revealed perturbations in complement/coagulation cascades, integrin signaling, and ECM–receptor interactions, suggesting that CDK4-related proliferative and microenvironment-associated networks may contribute to the observed effects of mCSS. Conclusion These findings support a multi-target anti-HCC effect of mCSS involving CDK4-associated signaling, whereas LGALS1-related stromal remodeling remains a predicted mechanism requiring further experimental validation.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: